Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Research with integrity – the importance of communication November 14, 2022 How My Metastatic Cancer Diagnosis Led Me to a Full-Time Career... July 15, 2021 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... July 7, 2021 Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Asciminib Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... Study Examines Whether Blood Test Can Identify Early Cancers Food for thought: new insights into how chemotherapy causes cachexia
